|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Ervik M, Lam F, Colombet M, Mery
L, Piñeros M, Znaor A, Soerjomataram I and Bray F: Global Cancer
Observatory: Cancer Today. International Agency for Research on
Cancer; Lyon: 2018
|
|
3
|
Yang J, Siri JG, Remais JV, Cheng Q, Zhang
H, Chan KK, Sun Z, Zhao Y, Cong N, Li X, et al: The Tsinghua-Lancet
Commission on Healthy Cities in China: Unlocking the power of
cities for a healthy China. Lancet. 391:2140–2184. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yadav D and Lowenfels AB: The Epidemiology
of Pancreatitis and Pancreatic Cancer. Gastroenterology.
144:1252–1261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H
and Zou X: Report of cancer incidence and mortality in China, 2010.
Ann Transl Med. 2:612014.PubMed/NCBI
|
|
6
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lambert A, Schwarz L, Borbath I, Henry A,
Van Laethem JL, Malka D, Ducreux M and Conroy T: An update on
treatment options for pancreatic adenocarcinoma. Ther Adv Med
Oncol. Sep 25–2019.(Epub ahead of print). doi:
10.1177/1758835919875568. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hammel P, Huguet F, van Laethem JL,
Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J,
André T, et al: LAP07 Trial Group: effect of chemoradiotherapy vs.
chemotherapy on survival in patients with locally advanced
pancreatic cancer controlled after 4 months of gemcitabine with or
without erlotinib: The LAP07 Randomized Clinical Trial. JAMA.
315:1844–1853. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Reilly EM and Hechtman JF: Tumour
response to TRK inhibition in a patient with pancreatic
adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol.
30:viii36–viii40. 2019. View Article : Google Scholar
|
|
10
|
Danussi C, Akavia UD, Niola F, Jovic A,
Lasorella A, Pe'er D and Iavarone A: RHPN2 drives mesenchymal
transformation in malignant glioma by triggering RhoA activation.
Cancer Res. 73:5140–5150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Y, Sheng R, Källberg M, Silkov A, Tun
MP, Bhardwaj N, Kurilova S, Hall RA, Honig B, Lu H, et al:
Genome-wide functional annotation of dual-specificity protein- and
lipid-binding modules that regulate protein interactions. Mol Cell.
46:226–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Steuve S, Devosse T, Lauwers E,
Vanderwinden JM, André B, Courtoy PJ and Pirson I: Rhophilin-2 is
targeted to late-endosomal structures of the vesicular machinery in
the presence of activated RhoB. Exp Cell Res. 312:3981–3989. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang G, He P, Tan H, Budhu A, Gaedcke J,
Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al:
Integration of metabolomics and transcriptomics revealed a fatty
acid network exerting growth inhibitory effects in human pancreatic
cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kohl M, Wiese S and Warscheid B:
Cytoscape: software for visualization and analysis of biological
networks. Data Mining in Proteomics. Springer; pp. 291–303.
2011
|
|
17
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
et al: AJCC Cancer Staging Manual. 8th edition. Springer; 2017
|
|
18
|
Fahimi HD: Cytochemical detection of
peroxisomes in light and electron microscopy with
3,3-diaminobenzidine. Methods Mol Biol. 1595:93–100. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang M, Duan T, Wang L, Tang J, Luo R,
Zhang R and Kang T: Low expression of centrosomal protein 78
(CEP78) is associated with poor prognosis of colorectal cancer
patients. Chin J Cancer. 35:622016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stark AP, Sacks GD, Rochefort MM, Donahue
TR, Reber HA, Tomlinson JS, Dawson DW, Eibl G and Hines OJ:
Long-term survival in patients with pancreatic ductal
adenocarcinoma. Surgery. 159:1520–1527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lal MA, Andersson AC, Katayama K, Xiao Z,
Nukui M, Hultenby K, Wernerson A and Tryggvason K: Rhophilin-1 is a
key regulator of the podocyte cytoskeleton and is essential for
glomerular filtration. J Am Soc Nephrol. 26:647–662. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang SY, Lu ZM, Lin YF, Chen LS, Luo XN,
Song XH, Chen SH and Wu YL: miR-144-3p, a tumor suppressive
microRNA targeting ETS-1 in laryngeal squamous cell carcinoma.
Oncotarget. 7:11637–11650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li B, Zhang S, Shen H and Li C:
MicroRNA-144-3p suppresses gastric cancer progression by inhibiting
epithelial-to-mesenchymal transition through targeting PBX3.
Biochem Biophys Res Commun. 484:241–247. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL,
Zhao JC, Liang GM, Feng ZB, Chen G and Luo DZ: A comprehensive
insight into the clinicopathologic significance of miR-144-3p in
hepatocellular carcinoma. OncoTargets Ther. 10:3405–3419. 2017.
View Article : Google Scholar
|
|
26
|
Li J, Sun P, Yue Z, Zhang D, You K and
Wang J: miR-144-3p induces cell cycle arrest and apoptosis in
pancreatic cancer cells by targeting proline-rich protein 11
expression via the mitogen-activated protein kinase signaling
pathway. DNA Cell Biol. 36:619–626. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang Z, Li X, Liu S, Li C, Wang X and
Xing J: MiR-141-3p inhibits cell proliferation, migration and
invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys
Res Commun. 514:699–705. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi Y, Zhao Y, Shao N, Ye R, Lin Y, Zhang
N, Li W, Zhang Y and Wang S: Overexpression of microRNA-96-5p
inhibits autophagy and apoptosis and enhances the proliferation,
migration and invasiveness of human breast cancer cells. Oncol
Lett. 13:4402–4412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu B, Zhang J and Yang D: miR-96-5p
promotes the proliferation and migration of ovarian cancer cells by
suppressing Caveolae1. J Ovarian Res. 12:572019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Ma N, Li W and Wang Z:
MicroRNA-96-5p promotes proliferation, invasion and EMT of oral
carcinoma cells by directly targeting FOXF2. Biol Open. 9:92020.
View Article : Google Scholar
|
|
31
|
Zhou HY, Wu CQ and Bi EX: MiR-96-5p
inhibition induces cell apoptosis in gastric adenocarcinoma. World
J Gastroenterol. 25:6823–6834. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi C, Yang Y, Zhang L, Yu J, Qin S, Xu H
and Gao Y: MiR-200a-3p promoted the malignant behaviors of ovarian
cancer cells through regulating PCDH9. OncoTargets Ther.
12:8329–8338. 2019. View Article : Google Scholar
|
|
33
|
Tang W, Yu X, Zeng R and Chen L:
LncRNA-ATB promotes cisplatin resistance in lung adenocarcinoma
cells by targeting the miR-200a/β-catenin pathway. Cancer Manag
Res. 12:2001–2014. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Ke F, Chen T, Zhou Q, Weng L, Tan
J, Shen W, Li L, Zhou J, Xu C, et al: MicroRNAs that regulate PTEN
as potential biomarkers in colorectal cancer: A systematic review.
J Cancer Res Clin Oncol. 146:809–820. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Ma Z, Liu X, Zhang C, Hu Y, Ding
L, Qi P, Wang J, Lu S and Li Y: MiR-183-5p is required for
non-small cell lung cancer progression by repressing PTEN. Biomed
Pharmacother. 111:1103–1111. 2019. View Article : Google Scholar : PubMed/NCBI
|
